Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (11448)	12/29/2017 2:00:00 AM
From: Miljenko Zuanic	Respond to of 12215

Thanks Jim for respond. I am not in mode to compare compounds directly (MGL-3196 is more complicated by structure, I am not medicinal chemist... but there were some efforts at Roche to develop liver-specific beta-compounds), still 2809 is odes at 10-20 mg/day while 3196 at 100mg/day. maybe ( as I was early) someone is confused that VK2809 is Sobetirome (http://en.pharmacodia.com/web/drug/1_14272.html), and actually it is MB-07811 (http://en.pharmacodia.com/web/drug/1_2986.html)....somehow interesting compound as well. In all, seams as VK2809 is well selective for liver (good absorption) and sufficiently selective to beta versus alpha sub-junit. Looking forward to P2 results. Prosperous New Year to ALL!